Our theranostics pipeline.
Targeted compounds paired with AI dosimetry across three tumour types. Each programme is built around the same patient-specific PK modelling framework.
Programme status overview.
| Compound | Indication | Target | Preclinical | Phase I | Phase II |
|---|---|---|---|---|---|
| YSO-001 | Prostate Cancer | PSMA | |||
| YSO-002 | Thyroid Cancer | TG / Iodine uptake | |||
| YSO-003 | Neuroendocrine Tumours | SSTR | |||
| YSO-004 | Prostate Cancer (2nd line) | PSMA (resistant) |
Three tumour types. One dosimetry framework.
Each indication has distinct receptor biology and pharmacokinetic characteristics. YSOTOPE's PK framework is validated across all three.
Prostate Cancer
PSMA receptor expression varies substantially between patients and declines over treatment cycles, making fixed-activity Lu-177-PSMA prescriptions increasingly inaccurate after the first cycle. YSOTOPE's cycle-by-cycle PK modelling adjusts the dose recommendation as receptor expression evolves. YSO-004 extends the programme to the second-line setting, where altered expression patterns require a modified model.
Differentiated Thyroid Cancer
Radioiodine ablation for differentiated thyroid cancer is one of the oldest forms of targeted radionuclide therapy, yet most centres still use empiric fixed-dose protocols. I-124 PET allows true dosimetry-driven activity calculation before I-131 treatment. YSOTOPE's YSO-002 programme provides automated I-124 PET quantification and absorbed dose modelling to replace the empiric approach.
Neuroendocrine Tumours
Somatostatin receptor expression in neuroendocrine tumours is highly heterogeneous between lesions in the same patient, and receptor density changes across cycles of Lu-177 DOTATATE therapy. YSOTOPE quantifies inter-lesion uptake differences from serial quantitative SPECT and models dose to the kidney as the primary organ-at-risk constraint across treatment cycles.